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Timing Isn’t Everything:
Donor Heart Allocation
in the Present LVAD Era*
Sean P. Pinney, MD
New York, New York
Trust in an organ allocation system is predicated on fairness,
a belief that organs will be directed to the most deserving
patients first. To this end, the Organ Procurement and
Transplantation Network contractor, the United Network
for Organ Sharing (UNOS), created a system that priori-
tizes the allocation of hearts to patients with the highest
likelihood of dying while waiting for a donor organ. Revised
in 2006 to incorporate broader regional sharing, this allo-
cation system has succeeded in directing hearts to a greater
proportion of high-urgency patients (UNOS 1A) and in so
doing reduced waiting list mortality without compromising
post-transplant outcomes (1).
See pages 36 and 44
This new allocation system left in place a provision for the
elective use of 30 days of high-urgency status, commonly
referred to as 1A time, for recipients of implantable left
ventricular assist devices (LVAD). The rationale for grant-
ing this specialized status stemmed from an earlier experi-
ence with pulsatile, implantable LVADs in which the
mortality in the first 3 weeks after LVAD surgery was 5% to
10% per week (2). These LVAD recipients were granted 30
days of 1A status from the date of LVAD implant, but some
experienced inferior outcomes by proceeding with trans-
plant surgery so soon thereafter. Recognizing that LVAD-
supported patients remained at risk of device failure over
time, a provision was made to allow them to carry forward
these 30 prioritized days to be used at any time at the listing
center’s discretion. This prioritization has remained even
after the emergence of continuous flow LVADs, which are
less likely to fail and have produced higher survival rates (3).
This has created a perception of stable patients being able to
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has cast doubt as to whether the UNOS donor heart allocation
system in its present configuration is indeed fair (4).
To be considered fair and balanced, an organ allocation
system must be guided by 2 ethical principles, maximizing
utility and distributing resources justly. These 2 ideals are
occasionally at odds with one another whereby prioritizing
one compromises the other. If one wanted simply to
maximize the utility of a transplanted heart by focusing on
the number of years of life gained, older recipients or those
with certain comorbidities would be passed over in favor of
younger, more robust recipients with a greater life expec-
tancy after transplant. Conversely, in prioritizing justice, one
would choose to ensure equal access to lifesaving organs,
usually in the face of greatest need, regardless of the outcome.
Heart transplant programs must also be guided by these
principles when deciding the appropriateness of transplant
for an individual candidate and when considering how best
to manage deserving patients while awaiting transplanta-
tion. Such decisions boil down to answering 4 practical
questions: First, what are the expected outcomes with and
without a transplant? Second, what are the expected out-
comes while waiting for a donor heart? Third, what are the
expected outcomes after LVAD surgery? Finally, what is the
expected survival after transplant, whether bridged with
medical therapy or with an LVAD?
In this issue of the Journal, we are provided some insight
into 2 of these questions. In the first paper, Teuteberg et al.
(5) evaluated the discriminatory value of the Destination
Therapy Risk Score (DTRS) in patients receiving a contin-
uous flow LVAD, the HeartMate II (Thoratec Corpora-
tion, Pleasanton, California). They retrospectively analyzed
prospectively collected data from 2 mechanical circulatory
support trials including 1000 patients. They discovered
that the DTRS was a poor mortality risk discriminator for
bridge to transplant recipients and a modest discriminator
for destination therapy patients. Furthermore, the score
failed to characterize a population in whom mechanical
support would be futile. The authors are to be congratulated
for providing us with a cautionary tale about prematurely
adopting risk predictor models into clinical decision mak-
ing. Even though this DTRS has been widely applied and
almost universally accepted, this score was never sufficiently
prospectively validated. Not only did the DTRS fail to
risk-stratify recipients of a continuous flow pump, but it
failed to effectively risk-stratify destination therapy recipi-
ents of a HeartMate XVE, a population similar to the
derivation cohort. This is an important and timely observa-
tion for those working in the field of mechanical support, a
field that depends on accurate and effective risk predictor
models to advise patients and inform clinical decision
making.
In an adjoining paper, Dardas et al. (6) examined the
outcomes for wait-listed registrants to examine whether
disparities in risk exist within and between UNOS status
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collected by the Scientific Registry of Transplant Recipients
from 2005 to 2010, a period of time characterized by the
transition from first-generation pulsatile LVADs to smaller
continuous flow devices. They report that the chance of
experiencing an adverse event (death or wait-list removal for
ineligibility) varied significantly within status 1A indica-
tions. Those with the lowest risk were LVAD patients using
elective 30-day 1A time (1% cumulative hazard) followed by
those on medical therapy (6%), LVAD complication (6%),
and 1A paracorporeal ventricular assist devices (15%). Over
this time period, candidates listed status 1A with an
implanted LVAD without complication increased from
11% to 26%, while those on medical support decreased from
44% to 39%. There were no significant differences in
survival after status 1A transplantation except for those
patients who were previously ventilator dependent.
Should clinically stable LVAD patients continue to
receive prioritization for donor hearts? Dardas et al. (6)
contend that they should not because doing so violates the
justice principle. First, they cite the higher risk for adverse
events in medically supported or mechanically ventilated
patients and suggest that these patients may be disenfran-
chised by preferentially allocating hearts to stable LVAD
patients who have the lowest risk of wait-list mortality.
Second, they argue that there is no utilitarian reason to
prioritize stable LVAD recipients because transplant out-
comes are not superior in this group compared with other
1A or 1B subgroups. Third, they suggest that in an ideal
system there should be no disparity and that all 1A patients
should be at equal risk.
These are compelling arguments but not persuasive.
Consider the following in rebuttal. First, there is no direct
evidence that prioritizing stable LVAD patients has pre-
vented other 1A patients from receiving timely transplants.
In fact, wait-list mortality has actually gone down (1). It is
likely that centers are exercising good judgment by timing
these upgrades to avoid competition with other 1A patients,
thereby preserving their exposure to donor hearts. Second,
before concluding that in the absence of a utilitarian reason
there is no rationale to justify 1A prioritization one should
be reminded of the German experience (7). In the Eu-
rotransplant system, there is no prioritization for stable
LVAD patients, which effectively eliminates the likelihood
of their receiving a transplant in the absence of developing
a device complication. Choosing to remain in urgent status
on medical therapy instead of accepting an LVAD may
increase the odds of receiving a transplant but does so at the
risk of dying or becoming ineligible while waiting. Patients
who opt for watchful waiting but end up requiring bailout
LVAD placement have inferior survival while on the wait-
ing list and, among the few who receive a heart, after dtransplant. Finally, even if one were to craft an entirely new
allocation system, disparities in risk would still exist. Con-
sider the authors’ own data. Patients supported with para-
corporeal ventricular assist devices or mechanical ventilation
had risk profiles exceeding those of the other 1A categories,
including those who are medically supported or have an
LVAD complication.
Despite these differences in opinion, there is agreement
that the current allocation system needs further refinement.
The widespread adoption of smaller, continuous flow
LVADs has begun to deliver on the promise of minimizing
the risk of mechanical support and maximizing its beneficial
outcomes. They are also improving the short- and mid-term
survival of transplant-eligible recipients. How UNOS ad-
justs to this changing landscape is not yet clear. The
adoption of a heart allocation score, similar in principle to
the model for end-stage liver disease or the lung allocation
score, is one possibility. Another is to expand the number of
prioritization categories matching individual risk profiles.
Regardless of which system emerges, facilitating this change
will require robust data collection and analysis similar to the
ones published today to achieve a fair and balanced system
for our patients.
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